Hydroxychloroquine alone or in combination with azithromycin and corrected QT prolongation in COVID-19 patients: A systematic review

Table 1 The baseline details of studies included in meta-analysis

Ref.	Study design	Population	Mean age	Male/female	HTN	DM	Medication
Afsin et al[12], Turkey	Retrospective	76	61 ± 14	32/44	41	26	Hydroxychloroquine plus Moxifloxacin
Bakhshaliyev et al[13], Turkey	Retrospective	109	57 ± 14	48/61	49	32	Hydroxychloroquine plus azithromycin
Bernardini et al[14], Italy	Retrospective	53	67 ± 12	37/16	21	6	Hydroxychloroquine plus azithromycin
Bun et al[15], France	Prospective	73	62 ± 14	49/24	33	19	Hydroxychloroquine plus azithromycin
Chorin et al[16], United States	Retrospective	251	64 ± 13	75/176	54	27	Hydroxychloroquine plus azithromycin
Cipriani et al[17], Italy	Retrospective	22	64 ± 11	18/4	12	6	Hydroxychloroquine plus azithromycin
Hsia et al[18], United States	Retrospective	105	67 ± 15	58/47	51	41	Hydroxychloroquine plus azithromycin
Maraj et al[19], United States	Retrospective	91	62 ± 15	51/40	42	26	Hydroxychloroquine plus azithromycin
Mercuro et al[20], United States	Prospective	90	60 ± 16	46/44	48	26	Hydroxychloroquine plus azithromycin
Ramireddy et al[21], United States	Retrospective	98	62 ± 17	60/38	59	22	Hydroxychloroquine plus azithromycin
Rodrıguez et al[22], Spain	Retrospective	161	63 ± 14	103/42	71	25	Hydroxychloroquine plus azithromycin
Saleh et al[23], United States	Prospective	201	58 ± 9	115/86	84	65	Hydroxychloroquine plus azithromycin
Saleh et al[24], United States	Retrospective	6476	64 ± 15	3980/2496	3184	2161	Hydroxychloroquine plus azithromycin
Sinkeler et al[25], Netherlands	Retrospective	397	67 ± 12	262/135	---	---	Hydroxychloroquine
van den Broek et al[26], Netherlands	Retrospective	95	65 ± 12	63/32	---	---	Hydroxychloroquine